Celyad Oncology chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.02
Market capitalization 24.11M
Operating cash flow -30.77M
ESG Scores unknown

Company description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.94M 1.16M -1.73M 2.96M
Total Cashflows From Investing Activities 607k 8.99M 157k -126k
Net Borrowings 201k -1.49M -1.45M -1.14M
Total Cash From Financing Activities 43.93M 18.28M 5.4M 39.52M
Change To Operating Activities
Issuance Of Stock 46.15M 18.17M 36.57M 36.57M
Net Income -37.43M -28.63M -17.2M -26.51M
Change In Cash 17.29M -1.2M -22.1M 12.78M
Effect Of Exchange Rate 3k -264k 8k 32k
Total Cash From Operating Activities -27.25M -28.2M -27.66M -26.64M
Depreciation 1.11M 1.79M 1.75M 1.44M
Change To Account Receivables -1.46M -1.77M -1.15M -1.56M
Other Cashflows From Financing Activities -2.42M 1.59M 6.84M 4.09M
Change To Netincome 8.58M -748k -9.42M -3.06M
Capital Expenditures -833k -417k -150k -331k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 23.58M 25.08M 21.44M 20.69M
Income Before Tax -37.43M -28.64M -17.2M -26.5M
Net Income -37.43M -28.63M -17.2M -26.51M
Selling General Administrative 10.39M 9.19M 9.39M 9.99M
Gross Profit 3.12M 6k 5k
Ebit -32.38M -29.49M -26.24M -27.24M
Operating Income -32.38M -29.49M -26.24M -27.24M
Interest Expense -62k -343k -297k -255k
Income Tax Expense -8k 10k
Total Revenue 3.12M 6k 5k
Cost Of Revenue
Total Other Income ExpenseNet -5.04M 854k 9.04M 735k
Net Income From Continuing Ops -37.43M -28.63M -17.2M -26.51M
Net Income Applicable To Common Shares -37.43M -28.63M -17.2M -26.51M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 38.71M 44.22M 35.09M 36.3M
Total Stockholder Equity 55.59M 45.62M 30.99M 43.64M
Other Current Liabilities 1.3M 1.36M 4.01M 4.18M
Total Assets 94.3M 89.84M 66.08M 79.94M
Common Stock 41.55M 48.51M 48.51M 78.58M
Other Current Assets 91k 150k 220k 246k
Retained Earnings -217.78M -74.42M -283.04M -309M
Treasury Stock 25.67M 28.18M 222.17M 267.73M
Cash 40.54M 39.34M 17.23M 30.02M
Total Current Liabilities 9.65M 11.92M 11.83M 13.83M
Other Stockholder Equity 25.67M 28.18M 222.17M 267.73M
Property, Plant, and Equipment 3.01M 5.06M 4.12M 3.25M
Total Current Assets 51.69M 42.84M 19.7M 34.29M
Net Tangible Assets 20.1M 10.03M -4.64M 7.95M
Net Receivables 1.27M 2.7M 907k 2.34M
Accounts Payable 5.92M 6.97M 4.74M 6.61M


Insider Transactions

Here are the insider transactions of stock shares related to Celyad Oncology:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Celyad Oncology. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Celyad Oncology

Here is the result of two systematic investment strategies applied to Celyad Oncology. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Celyad Oncology

The following chart shows the equity curve of the two systematic investment strategies applied to Celyad Oncology:

Celyad Oncology automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -64.07% on the backtest period.

Performance at glance

Performance

-64.07 %

Latent gain

-1131.74 $

Invested capital

1766.48 $

Annualized return

-15.63 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Celyad Oncology

This is the result of two momentum investment strategies applied to Celyad Oncology. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Celyad Oncology

The following chart shows all the entries opened by the momentum investment system on Celyad Oncology:

Celyad Oncology momentum entries
  • The first momentum investment strategy would give -58.76% of return on Celyad Oncology. That represents -3235.73$ of latent gain with 5506.31$ of employed capital.
  • The second momentum investment strategy would give -61.83% of return on Celyad Oncology. That represents -3091.69$ of latent gain with 5000.17$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-58.76 %

Latent gain

-3235.73 $

Invested capital

5506.31 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-61.83 %

Latent gain

-3091.69 $

Invested capital

5000.17 $

Annualized return

-17.08 %

Momentum equity curve on Celyad Oncology

The following chart shows the equity curve of the two momentum strategies applied to Celyad Oncology:

Celyad Oncology momentum equity

Note: the dividends potentially given by Celyad Oncology are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Celyad Oncology

The following chart shows the employed capital evolution of the two momentum strategies on Celyad Oncology since the beginning:

Celyad Oncology

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Celyad Oncology

Buy the dip entry openings on Celyad Oncology

Celyad Oncology

The performance achieved by the robo-advisor on Celyad Oncology is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Celyad Oncology stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Celyad Oncology, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Celyad Oncology

The following chart shows the result of the investment strategy applied to Celyad Oncology:

Celyad Oncology

Note: the dividends potentially given by Celyad Oncology are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Celyad Oncology

The following chart shows the employed capital evolution since the beginning of the investment strategy on Celyad Oncology:

Celyad Oncology

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Celyad Oncology

In this section, I will compare the three previous investment strategies applied to Celyad Oncology.

Equity curve comparison on Celyad Oncology

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Celyad Oncology investment strategy comparison

Employed capital comparison on Celyad Oncology

Celyad Oncology investment comparison

Performance comparison on Celyad Oncology

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -64.07% -1131.74$ 1766.48$ -15.63%
Momentum 1 quarter -58.76% -3235.73$ 5506.31$ -15.22%
Momentum 2 quarters -61.83% -3091.69$ 5000.17$ -17.08%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-15.63 %

Momentum 1Q

-17.08 %

Momentum 2Q

-17.08 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Celyad Oncology:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • Cerence Inc

  • Note: The algorithm computes the probability of correlation between Celyad Oncology and the other stocks. There may be false positives or some missing correlated stocks. If the price of Celyad Oncology does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Celyad Oncology
    Country Belgium
    City Mont-Saint-Guibert
    Address Axis Business Park
    Phone 32 1 039 41 00
    Website www.celyad.com
    FullTime employees 95
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker CYAD
    Market www.nasdaq.com

    Celyad Oncology ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown